Careers in the US

Our total rewards philosophy is designed to attract, retain, and motivate top talent and the best performers at all levels of the company to drive achievement of business objectives and build value. We are committed to developing and maintaining competitive compensation and benefits programs designed to keep employees productive and engaged.  More specifically, our total rewards philosophy is designed to:

• Provide competitive cash compensation and benefits program;
• Provide variable pay programs based on the attainment of specific organizational and individual performance goals;
• Recognize and reward individual initiatives and achievements while integrating rewards with our annual company-wide performance goals;
• Align the interests of our employees with the interests of the company in a system that reflects a strong culture of pay for performance;
• Encourage competency building and professional growth by linking career development and performance management with total rewards; and
• Ensure that total rewards programs support our core values

Minaris Regenerative Medicine has had a strong history of steady growth over its 20+  years of operation as a leader within the cell and gene therapy industry it serves.

While the Minaris name was adopted only recently in 2020, the company it represents was founded in 1999, more than twenty years prior, as Progenitor Cell Therapy. The company was the first cell therapy-focused contract manufacturing and development organization for the cell therapy industry. As a private company, “PCT”, as it was known at the time, served numerous clients across the industry, and expanded its geographic footprint to include facilities in both Allendale, New Jersey, and Mountain View, California.

Minaris Regenerative Medicine has gone through a number of name changes due to the global expansion of our business, but the fundamental services and mission of the company have remained the same over its 20+  years as a contract development and manufacturing organization (CDMO) for the cell and gene therapy industry. Its changes in name have reflected purchase of the company by a new parent company, and more recently been made to unite its global network of facilities (US, Germany and Japan) under a common brand name.

Recognizing the opportunity presented to provide services to the fast-growing regenerative medicine market, the multinational company, Hitachi Chemical, purchased PCT in 2017 based on the reputation and established clientele of the company. Hitachi Chemical leveraged the know-how of the company to launch a sister facility in Yokohama, Japan to serve the Japan market. The group added Europe as a service region with the 2019 purchase of another industry leader, apceth Biopharma (established 2010), based in Munich, Germany. Together, this global organization was renamed under the brand Minaris Regenerative Medicine in 2020.  Hitachi Chemical was acquired by Showa Denko Group (now Resonac) in 2020.

Hitachi Chemical was renamed to Showa Denko Materials in 2020 after its purchase by the multinational company, Showa Denko Group. Hitachi, Ltd. sold Hitachi Chemical Co., Ltd. to Showa Denko K.K. in March 2020, and what is now “Minaris Regenerative Medicine” was part of that acquisition. Showa Denko Group and Showa Denko Materials were collectively renamed "Resonac" in January 2023.

The investment of Resonac in Minaris Regenerative Medicine has allowed for the expansion and planned expansion of the company’s capacity in all of its regions, including the establishment of its newest facility in Allendale, New Jersey and its recent expansion.